Latest filings (excl ownership)
15-15D
Suspension of duty to report
13 Oct 22
8-K
Changes in Control of Registrant
22 Jun 22
NT 10-Q
Notice of late quarterly filing
15 May 17
10-K
2016 FY
Annual report
31 Mar 17
CT ORDER
Confidential treatment order
20 Mar 17
8-K
Entry into a Material Definitive Agreement
15 Mar 17
8-K
Entry into a Material Definitive Agreement
2 Mar 17
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
29 Dec 16
8-K
Entry into a Material Definitive Agreement
5 Dec 16
10-Q
2016 Q3
Quarterly report
14 Nov 16
8-K
Entry into a Material Definitive Agreement
4 Nov 16
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
30 Sep 16
8-K
Entry into a Material Definitive Agreement
18 Aug 16
10-Q
2016 Q2
Quarterly report
15 Aug 16
8-K
Entry into a Material Definitive Agreement
27 Jul 16
CT ORDER
Confidential treatment order
27 Jul 16
DEF 14A
Definitive proxy
20 Jul 16
8-K
Regulation FD Disclosure
18 Jul 16
PRE 14A
Preliminary proxy
1 Jul 16
8-K
FluoroPharma Enters Development and Commercialization Agreement for China and Canada
9 Jun 16
8-K
Entry into a Material Definitive Agreement
31 May 16
10-Q
2016 Q1
Quarterly report
16 May 16
8-K
Entry into a Material Definitive Agreement
4 May 16
D
$1M in debt / options / securities to be acquired, sold $150K, 1 investor
6 Apr 16
10-K
2015 FY
Annual report
30 Mar 16
8-K
Entry into a Material Definitive Agreement
23 Mar 16
424B3
Prospectus supplement
8 Feb 16
EFFECT
Notice of effectiveness
8 Feb 16
CORRESP
Correspondence with SEC
5 Feb 16
S-1/A
IPO registration (amended)
4 Feb 16
S-1/A
IPO registration (amended)
28 Jan 16
S-1/A
IPO registration (amended)
26 Jan 16
8-K
Entry into a Material Definitive Agreement
25 Jan 16
8-K
Departure of Directors or Certain Officers
14 Jan 16
424B3
Prospectus supplement
7 Jan 16
EFFECT
Notice of effectiveness
7 Jan 16
POS AM
Prospectus update (post-effective amendment)
31 Dec 15
8-K
FluoroPharma Names Dr. Thomas Tulip, PhD Chief Executive Officer
29 Dec 15
UPLOAD
Letter from SEC
9 Dec 15
Latest ownership filings
No filings